ID

29377

Beschreibung

A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00636792

Link

https://clinicaltrials.gov/show/NCT00636792

Stichworte

Versionen (1)
  1. 21.03.18 21.03.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

21. März 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Follicular Lymphoma NCT00636792

Englisch

Eligibility Follicular Lymphoma NCT00636792

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female subject 18 years of age or older
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
pathological diagnosis of follicular lymphoma (any grade)
Beschreibung

Follicular Lymphoma Grade Any

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0024301
UMLS CUI [1,2]
C0441800
UMLS CUI [1,3]
C1552551
documented relapse or progression following prior antineoplastic therapy
Beschreibung

Recurrent disease Post Antineoplastic Therapy | Disease Progression Post Antineoplastic Therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0277556
UMLS CUI [1,2]
C0687676
UMLS CUI [1,3]
C2346834
UMLS CUI [2,1]
C0242656
UMLS CUI [2,2]
C0687676
UMLS CUI [2,3]
C2346834
have received 4 or more prior doses of rituximab
Beschreibung

Rituximab Dose Quantity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0393022
UMLS CUI [1,2]
C0178602
UMLS CUI [1,3]
C1265611
at least 1 measurable tumor mass (>1.5 cm in the long axis and >1.0 cm in the short axis that has not been previously irradiated, or has grown since previous irradiation
Beschreibung

Tumor Mass Measurable Quantity | Tumor Mass Long axis | Tumor Mass Short axis | Prior radiation therapy Absent | Tumor growth Post Prior radiation therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C3273930
UMLS CUI [1,2]
C1513040
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C3273930
UMLS CUI [2,2]
C0522487
UMLS CUI [3,1]
C3273930
UMLS CUI [3,2]
C0522488
UMLS CUI [4,1]
C0279134
UMLS CUI [4,2]
C0332197
UMLS CUI [5,1]
C0598934
UMLS CUI [5,2]
C0687676
UMLS CUI [5,3]
C0279134
no clinically significant central nervous system lymphoma
Beschreibung

Central nervous system lymphoma Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0742472
UMLS CUI [1,2]
C0332197
karnofsky performance status (kps) ≥50 (equivalent to eastern cooperative group oncology group [ecog] status ≤2
Beschreibung

Karnofsky Performance Status | ECOG performance status

Datentyp

boolean

Alias
UMLS CUI [1]
C0206065
UMLS CUI [2]
C1520224
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
diagnosed or treated for a malignancy other than non-hodgkin's lymphoma (nhl) within 2 years of first dose, or who were previously diagnosed with a malignancy other than nhl and have any radiographic or biochemical marker evidence of malignancy. subjects with prostate cancer who were treated with definitive radiotherapy and have a serum prostate-specific antigen (psa) <1 ng/ml are not excluded. subjects are also not excluded if they have had basal cell or squamous cell carcinoma of the skin that was completely resected, or any in situ malignancy that was adequately treated.
Beschreibung

Malignant Neoplasms | Cancer treatment | Exception Non-Hodgkin Lymphoma | Exception Therapeutic radiology procedure Prostate carcinoma | Exception Prostate specific antigen measurement | Exception Complete excision Basal cell carcinoma | Exception Complete excision Squamous cell carcinoma of skin | Exception Carcinoma in Situ Treated

Datentyp

boolean

Alias
UMLS CUI [1]
C0006826
UMLS CUI [2]
C0920425
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0024305
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1522449
UMLS CUI [4,3]
C0600139
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0201544
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0015250
UMLS CUI [6,3]
C0007117
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C0015250
UMLS CUI [7,3]
C0553723
UMLS CUI [8,1]
C1705847
UMLS CUI [8,2]
C0007099
UMLS CUI [8,3]
C1522326
prior treatment with velcade® or bendamustine
Beschreibung

Velcade | Bendamustine

Datentyp

boolean

Alias
UMLS CUI [1]
C1174739
UMLS CUI [2]
C0525079
antineoplastic (including unconjugated therapeutic antibodies and toxin immunoconjugates), experimental, or radiation therapy within 3 weeks before day 1 of cycle 1
Beschreibung

Antineoplastic Therapy | Monoclonal antibody unconjugated therapy | Toxin Immunoconjugates | Therapies, Investigational | Therapeutic radiology procedure

Datentyp

boolean

Alias
UMLS CUI [1]
C2346834
UMLS CUI [2]
C0854644
UMLS CUI [3,1]
C0040549
UMLS CUI [3,2]
C0243020
UMLS CUI [4]
C0949266
UMLS CUI [5]
C1522449
nitrosoureas within 6 weeks before day 1 of cycle 1
Beschreibung

Nitrosourea

Datentyp

boolean

Alias
UMLS CUI [1]
C0028210
radioimmunoconjugates within 10 weeks before day 1 of cycle 1
Beschreibung

Radioimmunoconjugates

Datentyp

boolean

Alias
UMLS CUI [1]
C0243019
autologous stem cell transplant within 3 months before day 1 of cycle 1, or prior allogeneic stem cell transplant at any time
Beschreibung

Transplantation of autologous hematopoietic stem cell | Allogeneic Stem Cell Transplantation

Datentyp

boolean

Alias
UMLS CUI [1]
C1831743
UMLS CUI [2]
C2242529
major surgery within 2 weeks before day 1 of cycle 1
Beschreibung

Major surgery

Datentyp

boolean

Alias
UMLS CUI [1]
C0679637
platelet transfusion within 7 days of day 1 of cycle 1 (applies to subjects enrolled in the dose escalation phase only. this does not apply to subjects enrolled in phase 2 of the study).
Beschreibung

Platelet Transfusion

Datentyp

boolean

Alias
UMLS CUI [1]
C0086818
ongoing therapy with corticosteroids. prednisone ≤15 mg per day or its equivalent is allowed.
Beschreibung

Steroid therapy | Prednisone U/day allowed | Prednisone Equivalent allowed

Datentyp

boolean

Alias
UMLS CUI [1]
C0149783
UMLS CUI [2,1]
C0032952
UMLS CUI [2,2]
C0456683
UMLS CUI [2,3]
C0683607
UMLS CUI [3,1]
C0032952
UMLS CUI [3,2]
C0205163
UMLS CUI [3,3]
C0683607
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Follicular Lymphoma NCT00636792

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
male or female subject 18 years of age or older
boolean
C0001779 (UMLS CUI [1])
Follicular Lymphoma Grade Any
Item
pathological diagnosis of follicular lymphoma (any grade)
boolean
C0024301 (UMLS CUI [1,1])
C0441800 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
Recurrent disease Post Antineoplastic Therapy | Disease Progression Post Antineoplastic Therapy
Item
documented relapse or progression following prior antineoplastic therapy
boolean
C0277556 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C2346834 (UMLS CUI [1,3])
C0242656 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C2346834 (UMLS CUI [2,3])
Rituximab Dose Quantity
Item
have received 4 or more prior doses of rituximab
boolean
C0393022 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
Tumor Mass Measurable Quantity | Tumor Mass Long axis | Tumor Mass Short axis | Prior radiation therapy Absent | Tumor growth Post Prior radiation therapy
Item
at least 1 measurable tumor mass (>1.5 cm in the long axis and >1.0 cm in the short axis that has not been previously irradiated, or has grown since previous irradiation
boolean
C3273930 (UMLS CUI [1,1])
C1513040 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C3273930 (UMLS CUI [2,1])
C0522487 (UMLS CUI [2,2])
C3273930 (UMLS CUI [3,1])
C0522488 (UMLS CUI [3,2])
C0279134 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0598934 (UMLS CUI [5,1])
C0687676 (UMLS CUI [5,2])
C0279134 (UMLS CUI [5,3])
Central nervous system lymphoma Absent
Item
no clinically significant central nervous system lymphoma
boolean
C0742472 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Karnofsky Performance Status | ECOG performance status
Item
karnofsky performance status (kps) ≥50 (equivalent to eastern cooperative group oncology group [ecog] status ≤2
boolean
C0206065 (UMLS CUI [1])
C1520224 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Malignant Neoplasms | Cancer treatment | Exception Non-Hodgkin Lymphoma | Exception Therapeutic radiology procedure Prostate carcinoma | Exception Prostate specific antigen measurement | Exception Complete excision Basal cell carcinoma | Exception Complete excision Squamous cell carcinoma of skin | Exception Carcinoma in Situ Treated
Item
diagnosed or treated for a malignancy other than non-hodgkin's lymphoma (nhl) within 2 years of first dose, or who were previously diagnosed with a malignancy other than nhl and have any radiographic or biochemical marker evidence of malignancy. subjects with prostate cancer who were treated with definitive radiotherapy and have a serum prostate-specific antigen (psa) <1 ng/ml are not excluded. subjects are also not excluded if they have had basal cell or squamous cell carcinoma of the skin that was completely resected, or any in situ malignancy that was adequately treated.
boolean
C0006826 (UMLS CUI [1])
C0920425 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0024305 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C1522449 (UMLS CUI [4,2])
C0600139 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0201544 (UMLS CUI [5,2])
C1705847 (UMLS CUI [6,1])
C0015250 (UMLS CUI [6,2])
C0007117 (UMLS CUI [6,3])
C1705847 (UMLS CUI [7,1])
C0015250 (UMLS CUI [7,2])
C0553723 (UMLS CUI [7,3])
C1705847 (UMLS CUI [8,1])
C0007099 (UMLS CUI [8,2])
C1522326 (UMLS CUI [8,3])
Velcade | Bendamustine
Item
prior treatment with velcade® or bendamustine
boolean
C1174739 (UMLS CUI [1])
C0525079 (UMLS CUI [2])
Antineoplastic Therapy | Monoclonal antibody unconjugated therapy | Toxin Immunoconjugates | Therapies, Investigational | Therapeutic radiology procedure
Item
antineoplastic (including unconjugated therapeutic antibodies and toxin immunoconjugates), experimental, or radiation therapy within 3 weeks before day 1 of cycle 1
boolean
C2346834 (UMLS CUI [1])
C0854644 (UMLS CUI [2])
C0040549 (UMLS CUI [3,1])
C0243020 (UMLS CUI [3,2])
C0949266 (UMLS CUI [4])
C1522449 (UMLS CUI [5])
Nitrosourea
Item
nitrosoureas within 6 weeks before day 1 of cycle 1
boolean
C0028210 (UMLS CUI [1])
Radioimmunoconjugates
Item
radioimmunoconjugates within 10 weeks before day 1 of cycle 1
boolean
C0243019 (UMLS CUI [1])
Transplantation of autologous hematopoietic stem cell | Allogeneic Stem Cell Transplantation
Item
autologous stem cell transplant within 3 months before day 1 of cycle 1, or prior allogeneic stem cell transplant at any time
boolean
C1831743 (UMLS CUI [1])
C2242529 (UMLS CUI [2])
Major surgery
Item
major surgery within 2 weeks before day 1 of cycle 1
boolean
C0679637 (UMLS CUI [1])
Platelet Transfusion
Item
platelet transfusion within 7 days of day 1 of cycle 1 (applies to subjects enrolled in the dose escalation phase only. this does not apply to subjects enrolled in phase 2 of the study).
boolean
C0086818 (UMLS CUI [1])
Steroid therapy | Prednisone U/day allowed | Prednisone Equivalent allowed
Item
ongoing therapy with corticosteroids. prednisone ≤15 mg per day or its equivalent is allowed.
boolean
C0149783 (UMLS CUI [1])
C0032952 (UMLS CUI [2,1])
C0456683 (UMLS CUI [2,2])
C0683607 (UMLS CUI [2,3])
C0032952 (UMLS CUI [3,1])
C0205163 (UMLS CUI [3,2])
C0683607 (UMLS CUI [3,3])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video